Pacira BioSciences (PCRX) Acquisitions (2019 - 2026)
Pacira BioSciences' (PCRX) quarterly Acquisitions came in at $335000.0 in Q1 2026, down 97.99% year-on-year from $16.7 million in Q1 2025, and down 97.99% quarter-over-quarter from $16.7 million in Q1 2025.
Pacira BioSciences (PCRX) Acquisitions (2019 - 2026) Analysis & Trends
Pacira BioSciences' Acquisitions history runs 3 years deep, the most recent figure standing at $335000.0 for Q1 2026.
- On a quarterly basis, Acquisitions fell 97.99% year-over-year to $335000.0 in Q1 2026; TTM through Mar 2026 was $335000.0, a 97.99% decrease from a year earlier, with the FY2025 full-year figure at $16.7 million, changed N/A from the prior year.
- Acquisitions declined to $335000.0 in Q1 2026 per PCRX's latest filing, from $16.7 million in the prior quarter.
- Across five years, Acquisitions topped out at $16.7 million in Q1 2025 and bottomed at $335000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Pacira BioSciences | 1.05 Bn | 846.97 Mn | 140.96 Mn | 335,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 335,000.00 |
| Mar 31, 2025 | 16.70 Mn |
| Dec 31, 2019 | -992,000.00 |